Saturday 17 October 2026
Export ARAY’s income statement to Excel — free account
Accuray Incorporated
ARAY Healthcare Medical Devices
Accuray Incorporated’s revenue for fiscal 2026 (year ended June 2026) was $401.9 million, down 12.3% from fiscal 2025. In the quarter to June 2026, revenue fell 20.9%, EPS fell 300.0%, free cash flow grew 117.8% and total debt rose 18.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.16
0.01
−5.88%
Follow ARAY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.44 | 0.23 | 0.11 | 0.08 | |
P/FCF ratio |
11.54 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
16.31 | (6.21) | (8.65) | 13.14 | |
P/B ratio |
3.21 | 1.86 | 1.16 | 0.76 | |
Price to Tangible BV |
49.08 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.58 | 0.42 | 0.34 | 0.34 | |
EV/EBITDA |
32.24 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
11.73 | 40.05 | (7.53) | (19.63) | |
EV/FCF |
15.23 | (66.78) | (5.56) | (10.61) | |
Quick Ratio |
0.61 | 0.52 | 0.50 | 0.57 | |
Current Ratio |
1.56 | 1.47 | 1.42 | 1.50 | |
Net Debt/EBITDA |
(8.20) | (10.65) | (20.39) | 10.74 | |
Debt/Assets |
27.87% | 27.85% | 29.94% | 32.99% | |
Debt/Equity |
2.06 | 2.34 | 3.21 | 3.51 | |
Asset Turnover |
0.97 | 0.94 | 0.92 | 0.88 | |
Operating CF/Net income |
(0.56) | 1.16 | 0.47 | (1.25) | |
Capex/Depreciation |
(0.53) | (0.80) | (0.11) | (0.11) | |
Interest Coverage |
(1.40) | (1.50) | (1.08) | 0.64 | |
Research and Development Expense of Revenue |
12.10% | 10.42% | 7.80% | 7.49% | |
Selling, General and Administrative Expense of Revenue |
28.20% | 18.50% | 18.76% | 18.73% | |
Intangible Assets out of Total Assets |
0.13 | 0.13 | 0.13 | 0.13 | |
Share Based Compensation of Revenue |
2.68% | 0.86% | 1.31% | 1.66% | |
Graham Net Nets |
(0.46) | (1.03) | (2.32) | (3.58) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.98%) | (35.37%) | (94.87%) | (153.85%) | |
Free Cash Flow Yield |
8.66% | (2.75%) | (53.43%) | (40.49%) | |
Revenue per Share |
0.79 | 0.85 | 0.84 | 0.82 | |
Operating CF per Share |
0.10 | (0.13) | (0.05) | 0.02 | |
Capex per Share |
(0.02) | (0.02) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.09 | (0.16) | (0.05) | 0.02 | |
Cash per Share |
0.54 | 0.35 | 0.31 | 0.34 | |
Shareholders Equity per Share |
0.52 | 0.44 | 0.34 | 0.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.52 | 0.44 | 0.34 | 0.34 | |
Free Cash Flow |
10.28 | (19.01) | (6.07) | 1.97 | |
Working Capital |
108.99 | 92.95 | 87.37 | 96.37 | |
Capital Expenditures |
(1.90) | (3.02) | (0.47) | (0.46) | |
Net Current Asset Value |
(91.35) | (102.20) | (112.68) | (114.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
73.08 | 74.12 | 71.38 | 75.30 | |
Average Payables |
46.10 | 48.76 | 49.56 | 37.29 | |
Average Inventory |
155.19 | 149.89 | 151.54 | 144.05 | |
Average Assets |
464.95 | 463.20 | 465.95 | 456.96 | |
Average Common Equity |
53.55 | 50.66 | 45.65 | 61.43 |
Columns are period end dates